Read by QxMD icon Read

breast cancer and lncRNA

Fei Ma, Xu Liu, Shibo Zhou, Wenjie Li, Chunxiao Liu, Michelle Chadwick, Cheng Qian
LncRNAs have been proven to play crucial roles in various processes of breast cancer. LncRNA FGF13-AS1 has been identified as one of the 25 downregulated lncRNAs in breast cancer through analyzing data from two cohorts and TCGA by another group of our lab. In this study, we report that FGF13-AS1 expression is decreased in breast cancer tissue compared with corresponding normal tissue, and the downregulation of FGF13-AS1 is associated with poor prognosis. Functional studies show that FGF13-AS1 inhibits breast cancer cells proliferation, migration, and invasion by impairing glycolysis and stemness properties...
February 13, 2019: Cancer Letters
Bin Zhou, Haiyan Guo, Jinhai Tang
BACKGROUND It is well documented that long non-coding RNAs (lncRNAs) are involved in the progression of multiple human tumors by sponging microRNAs (miRNAs). However, whether lncRNA TFAP2A-AS1 plays a role in the tumorigenesis of breast cancer (BC) remains undetermined. MATERIAL AND METHODS Real-time PCR (qRT-PCR) assay was performed to detect the relative mRNA expression of TFAP2A-AS1 and miR-933. Flow cytometry analysis, CCK-8 assay, and Transwell assay were applied to detect the effects of TFAP2A-AS1 overexpression on cell cycle, apoptosis, viability, and invasion of BC cells...
February 15, 2019: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
Zhanwei Xuan, Jiechen Li, Jingwen Yu, Xiang Feng, Bihai Zhao, Lei Wang
Recently, an increasing number of studies have indicated that long-non-coding RNAs (lncRNAs) can participate in various crucial biological processes and can also be used as the most promising biomarkers for the treatment of certain diseases such as coronary artery disease and various cancers. Due to costs and time complexity, the number of possible disease-related lncRNAs that can be verified by traditional biological experiments is very limited. Therefore, in recent years, it has been very popular to use computational models to predict potential disease-lncRNA associations...
February 8, 2019: Genes
Feiyu Chen, Ning Wang, Hor-Yue Tan, Wei Guo, Cheng Zhang, Yibin Feng
Cancer is one of the most pervasive causes of morbidity and mortality worldwide regardless of the fact that a majority of therapeutic strategies have been constantly invented. The survival rate of cancer patients remains unsatisfactory due to the late diagnosis, frequent metastasis and poor response to chemotherapeutics. Therefore, novel methods with high specificity and susceptibility for prompt diagnosis and precise treatment of cancer are imperative. Circulating RNA is located in bodily fluids, including urine, saliva, breast milk and naturally present in blood...
February 11, 2019: Cancer Biology & Therapy
Amita Vaidya, Zhanhu Sun, Nadia Ayat, Andrew Schilb, Xujie Liu, Hongfa Jiang, Da Sun, Josef Scheidt, Victoria Qian, Siyuan He, Hannah Gilmore, William P Schiemann, Zheng-Rong Lu
Long non-coding RNAs (lncRs), by virtue of their versatility and multilevel gene regulation, have emerged as attractive pharmacological targets for treating heterogenous and complex malignancies like triple-negative breast cancer (TNBC). Despite multiple studies on lncRNA functions in tumor pathology, systemic targeting of these "undruggable" macromolecules with conventional approaches remains a challenge. Here, we demonstrate effective TNBC therapy by nanoparticle-mediated RNAi of the oncogenic lncRNA DANCR, which is significantly overexpressed in TNBC...
February 11, 2019: Bioconjugate Chemistry
Xiaopeng Hu, Yun Liu, Yaying Du, Teng Cheng, Wenfei Xia
Background: Breast cancer was dangerous to women health. A growing number of evidences indicate that long non-coding RNAs (lncRNAs) have many functions in the development and progression of breast cancer and may serve as the markers of diagnosis or prognosis. BLACAT1 is one of lncRNA and the roles of it in breast cancer is not clear. In this study, it is aimed to explore the roles and molecular mechanisms of BLACAT1 in breast cancer. Results: We found BLACAT1 took part in breast cancer cell aggressive phenotype...
2019: Cell & Bioscience
Wei Sun, Xiaoen Xu, Yizhou Jiang, Xi Jin, Ping Zhou, Yirong Liu, Yajie Guo, Ding Ma, Wenjia Zuo, Shenglin Huang, Xianghuo He, Zhiming Shao
Luminal breast cancer (BC) has a sustained risk of late disease recurrence and death. Considerable numbers of patients suffer from anti-endocrine therapy resistance. Here, we identified a novel lncRNA whose expression is high in breast cancer and especially higher in luminal breast cancer, dubbed LOL (lncRNA of luminal), that acts as a natural sponge for let-7 microRNAs to regulate tumor growth and tamoxifen resistance. LOL overexpression in parental MCF-7 cells exhibited a proliferative advantage in the addition of tamoxifen than negative control...
February 5, 2019: International Journal of Cancer. Journal International du Cancer
A-X Liu, F Yang, L Huang, L-Y Zhang, J-R Zhang, R-N Zheng
OBJECTIVE: Long non-coding RNA (lncRNA) is a significant member of the non-coding RNA family. New evidence has shown that it plays a pivotal role in the processes of tumor genesis and development. According to previous verification, the lncRNA Tubulin Alpha 4B (TUBA4B) is a tumor-associated molecule, but how TUBA4B expresses and functions in breast cancer is still not clear. PATIENTS AND METHODS: We conducted this study to examine what expression and biological role TUBA4B plays in breast cancer...
January 2019: European Review for Medical and Pharmacological Sciences
Fubo Chen, Shengcai Qi, Xu Zhang, Jinjin Wu, Xi Yang, Raorao Wang
As a new group of important effector molecules involved in multiple cancer types, including breast cancer, lung cancer and oral squamous cell carcinoma, long noncoding RNAs (lncRNAs) have attracted considerable attention recently. However, the underlying cause that induces the dysregulated lncRNAs in cancer remains poorly understood. In the present study, the regulatory model of the lncRNA placenta‑specific protein 2 (PLAC2) upregulation in oral squamous cell carcinoma (OSCC) was investigated and its biological functions in OSCC malignant progression was identified...
February 1, 2019: International Journal of Oncology
Min Sun, Di Wu, Ke Zhou, Heng Li, Xingrui Gong, Qiong Wei, Mengyu Du, Peijie Lei, Jin Zha, Hongrui Zhu, Xinsheng Gu, Dong Huang
PURPOSE: To identify a lncRNA signature to predict survival of breast cancer (BRCA) patients. METHODS: A total of 1222 BRCA case and control datasets were downloaded from the TCGA database. The weighted gene co-expression network analysis of differentially expressed mRNAs was performed to generate the modules associated with BRCA overall survival status and further construct a hub on competing endogenous RNA (ceRNA) network. LncRNA signatures for predicting survival of BRCA patients were generated using univariate survival analyses and a multivariate Cox hazard model analysis and validated and characterized for prognostic performance measured using receiver operating characteristic (ROC) curves...
February 4, 2019: Breast Cancer Research and Treatment
Yue Cheng, Yiqi Pan, Yiyuan Pan, Ouchen Wang
Purpose: lncRNAs have recently been identified as key regulators of basic biological processes as well as the pathogenesis of various diseases. Previous studies have shown that lncRNA MNX1-AS1 promotes cell migration and invasion in ovarian cancer; however, its role in regulating breast cancer-associated biological processes remains unclear. Materials and methods: We obtained paired specimens of breast cancer tissues and adjacent normal tissues by modified radical mastectomy from 36 patients, in addition to four breast cancer cell lines (MDA-MB-231, MDA-MB-468, BT-549 and MCF-7)...
2019: Cancer Management and Research
Liuhong Zheng, Yuhan Zhang, Yajun Fu, Hangdi Gong, Jianjun Guo, Kangjing Wu, Qiaojun Jia, Xianfeng Ding
The human genome transcribes a large amount of noncoding RNAs, including long noncoding RNAs (lncRNAs) and microRNAs. LncRNAs and microRNAs have been shown to play a critical regulatory role in tumorigenesis and progression. Competitive endogenous RNAs (ceRNAs) affect other RNAs transcription through competitively binding to common microRNAs (miRNAs). MALAT1 is a typical lncRNA that is markedly up-regulated in breast cancer. However, current understanding of the involvement of MALAT1 in breast cancer development and prognosis remains unclear...
January 25, 2019: Bioscience Reports
Ye Zhang, Peng Lu, Huaping Du, Lifei Zhang
BACKGROUND LINK-A lncRNA acts as an oncogene in triple-negative breast cancer, but its involvement in other diseases is unknown. The present study was performed to investigate the involvement of LINK-A lncRNA in mantle cell lymphoma. MATERIAL AND METHODS Expressions of LINK-A lncRNA and survivin in plasma of patients with mantle cell lymphoma and healthy controls were detected by qRT-PCR and ELISA, respectively. ROC curve analysis was performed to investigate the diagnostic value of LINK-A lncRNA for mantle cell lymphoma...
January 12, 2019: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
Zhuo Li, Dehai Yu, Haijun Li, You Lv, Sijie Li
Tamoxifen is the gold standard for breast cancer endocrinotherapy. However, drug resistance remains a major limiting factor of tamoxifen treatment. Long non‑coding (lnc) RNA serves an important role in drug resistance; however, the molecular mechanisms of tamoxifen resistance in breast cancer endocrinotherapy are largely unclear. lncRNA urothelial cancer associated 1 (lncRNA UCA1, UCA1) has been proven to be dysregulated in human breast cancer and promotes cancer progression. In the present study, it was demonstrated that UCA1 was significantly upregulated in breast cancer tissues compared with healthy tissues...
January 8, 2019: International Journal of Oncology
Youyi Xiong, Yuanting Gu, Fang Wang, Lin Li, Mingzhi Zhu, Nan Wang, Hailong Mi, Xinguang Qiu
Breast cancer is a one of the most malignant threats among women worldwide. However, the mechanism underlying breast cancer development remains unclear. Long noncoding RNAs (lncRNAs) have been reported to participate in breast cancer. Whether lncRNA LINC01857 is involved in breast cancer requires investigation. In this study, we found that LINC01857 was highly expressed in breast cancer tissues and cells (p < 0.05). High LINC01857 expression predicted poor prognosis in breast cancer patients. Functionally, LINC01857 silencing impaired proliferation and enhanced apoptosis of breast cancer cells ( p < 0...
January 9, 2019: Journal of Cellular Physiology
Lifeng Dong, Junbin Qian, Fangfang Chen, Yangfan Fan, Jingpei Long
Mounting evidence has demonstrated that long noncoding RNAs (lncRNAs) are dysregulated and implicated in the occurrence and development of a wide range of human malignancies. LINC00461, a novel cancer-related lncRNA, has been reported to be highly expressed and serve as oncogene in glioma; however, its biological role in breast cancer (BC) remains obscure. This study aimed to explore the role of LINC00461 in BC and elucidate the potential molecular mechanisms involved. In the current study, LINC00461 was found to be significantly upregulated in both BC tissues and cell lines...
January 8, 2019: Journal of Cellular Biochemistry
Huaying Dong, Jianguo Hu, Kejian Zou, Mulin Ye, Yuanwen Chen, Chengyi Wu, Xin Chen, Mingli Han
BACKGROUND: Trastuzumab resistance followed by metastasis is a major obstacle for improving the clinical outcome of patients with advanced human epidermal growth factor receptor 2-positive (HER-2+) breast cancer. While long non-coding RNAs (lncRNAs) can modulate cell behavior, the contribution of these RNAs in trastuzumab resistance and metastasis of HER-2+ breast cancer is not well known. In this study, we sought to identify the regulatory role of lncRNA in trastuzumab resistance and accompanied Epithelial-mesenchymal Transition (EMT) process in advanced HER-2+ breast cancer...
January 8, 2019: Molecular Cancer
Jie Li, Chundi Gao, Cun Liu, Chao Zhou, Xiaoran Ma, Huayao Li, Jia Li, Xue Wang, Lingyu Qi, Yan Yao, Xiaoming Zhang, Jing Zhuang, Lijuan Liu, Kejia Wang, Changgang Sun
Previous studies on long noncoding RNA (lncRNA) have made breakthroughs in the treatment of several tumors, and these findings have brought attention to the lncRNA signature of breast cancer. Increased understanding of genomic architecture and achievement of innovative therapeutic strategies has prompted creation of a novel oncological model for the treatment of solid cancers. In this study, we systematically analyzed the transcriptome of breast cancer tissues to gain more in-depth knowledge of tumor biology...
January 7, 2019: Journal of Cellular Physiology
Xiaolong Wang, Tong Chen, Yan Zhang, Ning Zhang, Chen Li, Yaming Li, Ying Liu, Hanwen Zhang, Wenjing Zhao, Bing Chen, Lijuan Wang, Qifeng Yang
Recently, long noncoding RNAs (lncRNAs) have become the key gene regulators and prognostic biomarkers in various cancers. Through microarray data, Linc00339 was identified as a candidate oncogenic lncRNA. We compared the expression levels of Linc00339 in several breast cancer cell lines and normal mammary gland epithelial cell line. The effects of Linc00339 on tumor progression were examined both in vitro and in vivo. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays were applied to evaluate the functions of Linc00339, miR-377-3p, and HOXC6 on cell proliferation...
January 7, 2019: Journal of Cellular Physiology
Carolina Mathias, Erika Pereira Zambalde, Daniela Fiori Gradia, Jaqueline Carvalho de Oliveira, Philip Rask
Breast Cancer (BC) is the most commonly diagnosed cancer and is the leading cause of cancer deaths in women. BC is a heterogeneous disease with different clinical and genetic features. According to immunohistochemical markers, BC is subdivided into four main subtypes: luminal A, luminal B, ERBB2-positive and triple negative. Long non-coding RNAs (lncRNAs) are transcripts with more than 200 nucleotides and deregulated lncRNAs are associated with human diseases, including BC. In order to improve BC molecular classification, non-coding RNAs (ncRNAs), including lncRNAs, have been used...
January 7, 2019: Clinical Genetics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"